About PolpharmaWe are the largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market. We actively operate in the markets of Central and Eastern Europe, the Caucasus and Central Asia.
Sustainable development/ESG“We help people live healthy lives in a healthy world”. This is our mission, which reflects Polpharma’s priorities. We provide patients with high-quality, effective, safe and accessible products while operating responsibly in the society, the environment and with respect to key stakeholders.
CareerPolpharma's development is possible only thanks to the commitment of our employees as well as the involvement of students and graduates in various business areas.
In connection with the implementation of the project entitled "Development and introduction to the market of the first non-antibiotic product for the treatment of infectious eye diseases with an innovative ophthalmological composition in the form of eye drops, containing an active substance - povidone iodine" funded by the state budget…
The Polpharma Scientific Foundation was established in 2001. Its mission - expressed by the slogan “We help people of science” - is to support the development of pharmaceutical and medical sciences by financing scientific research. The main goal of the foundation is to finance research projects of exceptional importance for…
Polpharma ranked third in the pharmaceutical and medical industry in the 18th edition of the "ESG Ranking. Responsible Management". The ranking, organized by Koźminski Business Hub at the Leon Koźmiński Academy, represents a new version of the Responsible Companies Ranking, which has long been regarded as a market benchmark for…
Warszawskie Zakłady Farmaceutyczne Polfa S.A. invites tenders for the purchase of used line for ampoules visual inspection and leak detection. The line includes the following devices: Inspection device EISAI: AIM 296/T, manufactured: 1997, Ampoule head inspection device: ZMR UKA-01 , manufactured: 2017, Leak detection device: Brevetti LTM, manufactured: 2004. …
The idea behind the programme is to encourage all companies in Poland to adhere to the principles of ethics and to introduce the necessary changes, not only as regards internal work organization, but also as regards shaping a positive relationship with the local community and protecting the natural environment. Polpharma…
Warszawskie Zakłady Farmaceutyczne Polfa S.A. invites tenders for the purchase of used Bosch filling line for glass vials. The line includes the following devices: Vials washer: RRU2033, Depyrogenation Tunnel: HQL 3460, Filling device: FLC 3040 DP, Capping machine: VRK 2005 B. Line manufacturing year: 2008 Additional information regarding…
Warszawskie Zakłady Farmaceutyczne Polfa S.A. invites tenders for the purchase of used Bosch aseptic filling line for glass vials. The line includes the following devices: Vials washer: RRU2033, Depyrogenation Tunnel: HQL 3460, Filling device: FLC 3040 DP, Capping machine: VRK 2005 B. Line manufacturing year: 2008 Tenders containing: the completed…
Warszawskie Zakłady Farmaceutyczne Polfa S.A. invites tenders for the purchase of used aseptic filling line for ophthalmic liquids including the solution preparation units. The line includes the following devices: Filling and capping monoblock Groninger ZZB 1000/DFVK 6000/KVK 108, year: 2005, labeller Intrex SET 2991 Plus, year: 2017, cartoner Marchesini MA…
The ranking of national champions, prepared for the fourth time by Polityka Insight, demonstrates that Poland’s largest drug manufacturer – alongside PKN Orlen, KGHM, Asseco Poland and Jastrzębska Spółka Węglowa – is one of the greatest contributors to the development of modern Polish economy. Sebastian Szymanek, President of the Management…
Biotechnology is one of the strategic sectors of the Polish economy and as such, it has been included in the Strategy for Responsible Development. To foster the development of this innovative area, Poland needs investments in infrastructure and drug development, where Polpharma’s contribution will amount to a total of PLN…
We cooperate with the Polish and Ukrainian authorities, non-governmental organizations and authorized institutions so that our help reaches the places where it is most needed. In the first 3 weeks of the war, through the Government Strategic Reserves Agency, we donated over 350,000 packages of life-saving drugs, including antibiotics and…
What makes it even more special, is that Polpharma was one of only three awarded companies, not creative agencies – 97 out of 100 awards went to Poland’s best PR and marketing agencies. The idea behind the EcoVisit is to educate our customers about new technologies and e-visits and protect our climate…
Polpharma seeks EU funding to conduct R&D projects Since the accession of Poland to the European Union in 2004, Polpharma has been applying for financial support to implement innovative projects under different funding programmes, both national and European. By the end of 2009, Polpharma had been awarded co-funding of…
We have prepared a donation of several hundred thousand packages of hospital drugs, antibiotics and medications used in emergency medicine, which are most needed in Ukrainian hospitals. We cooperate on this matter with the Ministry of Health and the Governmental Agency for Strategic Reserves, which has the necessary knowledge in…
A bridge between science and business “Industry-supported doctoral degrees” is a flagship program of the Minister of Science and Higher Education, Jarosław Gowin. Its goal is to provide PhD students with opportunities to study in close cooperation with their employers or other businesses, for example, by using company equipment and…
The award was presented to the winner during a special session of the Senate of Medical University of Gdańsk, chaired by the University Rector, Professor Marcin Gruchała. The laudation speech was delivered by the Dean of the Faculty of Pharmacy, Professor Michał Markuszewski. He emphasized that it is thanks to…
“We are very pleased about the partnership between our two great companies. This collaboration demonstrates JGL’s strength and competitiveness on the global market and competence of our employees, especially in the field of ophthalmology which is our core therapeutic area,” said Mislav Vučić, the CEO of JGL, who signed the…
Markus’ previous experience in Medicines for Europe spans the range of priority topics for our sector, including the EU pharmaceutical legislation, Critical Medicines Act, the industry response to both the war in Ukraine and the global pandemic, as well as ongoing regulatory and digital improvements in health. Markus outlined the…
This is to inform you that on 1 April 2021 the companies POLPHARMA Biuro Handlowe sp. z o.o. with its registered office in Warsaw (00-728) at ul. Bobrowiecka 6 ("Polpharma BH") and Medana Pharma SA with its registered office at ul. Władysława Łokietka 10, in Sieradz (98-200) ("Medana") merged with…
We kindly inform you that on March 1, 2024 the company Warszawskie Zakłady Farmaceutyczne Polfa Spółka Akcyjna with registered office in Warsaw, Karolkowa 22/24 street (“Polfa Warszawa”) merged with Zakłady Farmaceutyczne “POLPHARMA” Spółka Akcyjna with registered office in Starogard Gdański, Pelplińska 19 street (“Polpharma”). The business combination fulfils one of…
The survey took place at the turn of 2022/2023, and over 12,000 students from 77 universities across Poland took part in it. Students evaluated the most important, in their opinion, attributes of an ideal employer, such as: friendly working environment, respect for employees and the ability to reconcile professional and…
In connection with the implementation of the project titled “Development(Description) and development of an innovative solution - a complex, two-component medicinal product in the form of eye drops in a multi-dose package without preservatives, aimed at the treatment of open-angle glaucoma", funded from the state budget by the Medical Research…
The new prescription drug packagings offered by Polpharma Group (including Polpharma, Medana and Polfa Warszawa) were created on the basis of interviews with patients and pharmacists and have been consulted with them every step of the way. The change also makes part of a strategic process of unification of the…
The parties declare their willingness to cooperate in implementing the concept of the Factory of the Future, which is the digitization of industrial processes in the entire value chain of pharmaceutical production, starting from the laboratory, through planning and execution of production cycles, machinery and equipment servicing, condition monitoring and…
"The elements of innovation and sustainable development are very important to us and we are happy that these initiatives are willingly supported by the Polish and international banking sector. I want to thank our financial partners for their trust, mutual understanding of common goals, and valuable collaboration" – says Wojciech…
Strengthening market position Polpharma, with almost 90 years of history, is one of the largest manufacturers of medicines in Central and Eastern Europe. With the acquisition of Ziołolek, Polpharma plans to expand its product range with unique products, mainly in the dermatological category, which have not previously been produced at…
74 companies participated in this year's fourteenth edition of the Ranking. Polpharma in the category "Consumer goods, pharmacy" took the highest place on the the podium ex equo with Coca-Cola HBC Polska, and in the general category second place ex equo with Santander Bank Polska, STU Ergo Hestia, Schenker and…
Forbes monthly published the ranking for the fourth time. "Once again Polpharma was among the largest Polish private companies, which makes us very happy. Thanks to the commitment of our owner, we are the largest investor in new products and modern infrastructure in Polish pharmaceutical sector. We are constantly developing,…
The contract that significantly extends the current scope of cooperation was signed on 19 June this year by Markus Sieger, CEO of Polpharma Group, and Daniel Franke, Managing Director of FM Logistic Central Europe. Under the contract, the facility to be provided to Polpharma by FM Logistic will become a…
Polpharma, the leader of Polish pharmaceutical sector and MSN Laboratories are delighted to announce a strategic distribution partnership. Polpharma, renowned for its leadership in the generic pharmaceutical market and its extensive experience in the production of high-quality pharmaceuticals, will leverage its strong distribution network and market expertise to introduce MSN…
We are proud to work with experienced professionals who are willing to share their knowledge, confirming the expert position of Polpharma API on the market. Tomorrow, on Thursday, October 22, Adam Hałuszczuk, the leader of the group responsible for risk management related to the presence of nitrosamines in active substances…
Digital technologies, such as Augmented Reality, the Internet of Things, or Artificial Intelligence, support better control and higher effectiveness of our production processes. It is possible thanks to a combination of innovative technologies and openness and the digital mindset of our employees. During ITM Industry Europe 2021 we had the…
This week, during the Health Protection Forum 2019 organized as part of the Economic Forum in Krynica with the participation of the most important Polish politicians, presidents of the largest companies, economists and experts from abroad, we received the “Innovation Leader” award in the Health Ranking. Polpharma has been recognized,…
The Ranking of Responsible Companies, first published in 2007, is a list of the largest companies in Poland assessed in terms of the quality of corporate social responsibility management. The substantive partners are the Responsible Business Forum and Deloitte, the media partner is Dziennik Gazeta Prawna, and the technological partner…
For many years, we have been implementing our social responsibility strategy, constantly improving our practices addressed to patients, employees, local communities, and other stakeholders. Our purpose is to help people to live a healthy life in a healthy world, therefore a concern for health and care for the environment are…
CPHI is the place where the entire pharmaceutical world meets. The substance suppliers, raw materials and technologies, as well as manufacturers of devices, packaging and ready-made medications present their offer here. The Polpharma Group will participate in CPHI for the 18th time. This is an excellent occasion to discuss cooperation opportunities, including in…
As a result of our employer branding activities focused on academic field, we maintained the leading position in Natural Sciences category, where we overtook such brands as, among other, Google, Ziaja, L’Oreal. We received this special award on June 17th, during the Universum Awards 2020 ceremony, where we were appreciated…
Based on Employees' votes, Polpharma was among the companies distinguished in the prestigious competition "Family-friendly Company / Human-friendly Company" (Family & Human Humanites Wellbeing Award 2020) organized by the Humanites Institute. This competition, referring to the role played by the mutual influence of family life and professional life, gained particular…
In this year's jubilee edition of the Polityka weekly rank, prepared in cooperation with the Responsible Business Forum and Deloitte, Polpharma received a special award - the Diamond CSR Leaf - alongside another Golden CSR Leaf. This way honoured were four companies who won the highest distinction of the rank,…
Polpharma was awarded for the effort it has put in promoting compliance with ethical standards. Markus Sieger, the CEO of Polpharma and member of the United Nations Global Compact Poland Programme Committee, received the statuette during the formal gala organised in connection with the United Nations Day celebrations on 15…
The Polpharma Digital Community is an initiative supporting the digital transformation process in the company. Its goal is to involve employees throughout the organization, building their awareness and the ability to use the potential of digitization. Thanks to the commitment of over 100 digitization ambassadors and over half of 4,200…
Confirmation of high standards The certificate is the result of the consistent implementation of the Sustainable Supply Chain strategy implemented in the Polpharma Group. It also confirmed the position of the company as a leader in developing the best market standards in the area of sustainable development in Poland. ISO…
Under Markus Sieger’s leadership, Polpharma Group has achieved significant growth - both financially and in its mission to build a purpose-driven organization: “We help people live healthy lives in a healthy world.” The company has become a trusted partner to healthcare systems across Europe and Central Asia, delivering high-quality, affordable…
Polpharma Group’s Corporate Social Responsibility Report has been drawn up in accordance with GRI Standards: Core Option and submitted for an independent external assurance. The Report’s contents were defined by the Polpharma Group representatives and external stakeholders. Polpharma presents its achievement in the field of CSR in a two-year cycle,…
Commitment to Health Security Public health is a fundamental right. As EU Health Ministries approach the final stages of negotiations on the future of Europe’s pharmaceutical rules, Polpharma Group emphasizes the need to ensure that every European has access to the medicines they need. This is about avoiding shortages, bringing…
The consortium of Polfa Warszawa (Polpharma Group) and IBCH PAS in Poznań was awarded the largest grant (PLN 93.8 million) in the competition for the implementation of RNA technology in Poland organized by the Medical Research Agency. RNA technology is a highly effective novel approach to the development of medicinal…
The letter, signed by CEOs and senior executives from across the European off-patent medicines sector, focuses on the need to: Accelerate the adoption of the EU pharmaceutical legislation, with a strong emphasis on: Maintaining the current 11-year regulatory exclusivity period to avoid unnecessary healthcare costs. Strengthening and harmonizing the Bolar…
Polpharma has opened a new specialized center in Starogard Gdański, dedicated to research and development, as well as the production of highly active pharmaceutical ingredients (HP API), used in the manufacturing of drugs, including oncology medications. This investment, valued at over 100 million PLN, is the only one of its…
The winners include the most active and effective companies in the field of ethics and CSR among all Polish businesses. An essential element of the evaluation was the quality of the ethics management system – something Polpharma had been developing for years, relying on its ethics and anti-corruption programme, as…
Polpharma came fifth in this year's ranking of National Champions prepared by the Polityka Insight analytical center. The ranking was published in the report entitled "National Champions 2020. How do they support human capital?". Polpharma was ranked fifth, ex aequo with Grupa Lotos and PGNiG. In previous years, the company…
We are proud to be recognized as a great place of work by the students. We pay a lot of attention to the professional satisfaction of our employees and their development as well as a friendly working environment. Every year, university students vote for their ideal employers in the world’s…
On 10 June, during a ceremony held at the Polish Prime Minister’s Office, Markus Sieger, CEO of Polpharma, signed an agreement with the Medical Research Agency to initiate the Warsaw Health Innovation Hub. This is the first initiative of its kind across Central Europe, aiming to bring together the public…
“Polpharma's purpose is to help people live a healthy life in a healthy world. A key role in our activity is played by the development of modern pharmaceutical products that respond to contemporary health challenges, ensure drug security and expand access to effective therapies for patients in Poland and Europe.…
According to the latest report of the European Patent Office (EPO) for 2022, Polpharma is the only company, next to Polish universities and research institutes, to have submitted the largest number of European patent applications. In the TOP-10 list for Poland, the leaders are the Jagiellonian University in Krakow (20 applications), the…
The award was collected by Agnieszka Deeg-Tyburska, Head of the Legal and Organizational Department, Legal Security and Patents, Member of the Management Board, and Oskar Filipowski, Head of the Compliance Team. As part of the competition, awards were given to companies that work to build and strengthen an organizational culture…
With great pride, we announce that we have become a Supporting Partner of the Huge Expedition of "Maluch" Cars for Children 2024 – a wonderful charity initiative aimed at supporting children affected by traffic accidents and preventing further tragedies through educating the youngest. Last year, there were 1,778 road accidents…
The 'Trustworthy Brand' survey is carried out every year and checks the level of trust in business brands. The survey is carried out by the Kantar Polska research institute on behalf of the magazine "MyCompany Polska". Based on their own experience and knowledge, the respondents selected companies that in their…
As a result of our employer branding activities focused on academic field, we maintained the leading position in Natural Sciences category, where we overtook such brands as Google and L’Oreal. We received this special award on June 18th, during the Universum Awards 2019 ceremonie, where we were appreciated by 18 000…
The goal of the Climate Leadership programme is to build a community of business leaders who, understanding the need of transformation to curb climate change, see it as an opportunity for development. Working with external Programme experts, companies develop and then implement solutions that measurably reduce their impact on the…
his is the third ranking list in the series published by Forbes. “Forbes’s list of the 100 largest Polish private companies reflects the condition of the economy and the status of private businesses in Poland. I am delighted to see Polpharma among the top ten companies yet again. We are the…
This year’s 13th edition of the Ranking saw 81 companies. Polpharma shared first place with BNP Paribas. In the industry category “Consumer Goods and Pharmaceuticals”, Polpharma was also awarded the top score. “This tremendous success is the result of the implementation of Polpharma Group’s CSR Strategy for 2015-2018 along with…
Announced for the second time, the National Champions Ranking featured Polpharma among the Top 10 Polish companies. “For the average person, a national champion is someone to be proud of. It’s usually associated with a domestic brand and that’s how it’s used. As a result, national champions help strengthen the…
The weekly Polityka has been rewarding companies that are guided by the values of corporate social responsibility (CSR) in their business activities for several years. The awards go to organizations that not only implement the guidelines of the international CSR standard (ISO 26000), but also have developed and implemented their…
The new location will enable Polpharma to work more closely with key API suppliers, improve process predictability, and support the advancement of high quality and ESG standards across the region. “India is a global center of excellence for APIs – it’s the fact we cannot ignore, despite advocating for building…
Technology, safety and products of the highest quality The center's cutting-edge technology and high standards will allow the development and production of substances that help patients in the fight against oncological diseases, multiple sclerosis or spinal myositis (SMA), among others. As a first step, the substances that will be produced…
StartSmart CEE is one of the largest initiatives of its kind in Central and Eastern Europe with over 3,000 emerging tech companies from various countries having participated so far, and more than 300 of which have received real support. The partners for the Spring 2024 edition are: Warner Bros, Discovery…
The cooperation involves manufacturing of the drug substance of the clinical candidate PKL-021, needed to support the preclinical research program and the production of an investigational medicinal product for the phase one clinical trial. The manufacturing process will be conducted by Polpharma, in accordance with the Good Manufacturing Practice (GMP)…
As Poland’s largest manufacturer of medicines, including hospital drugs used in the treatment of covid complications, we are aware of the related responsibility. That is why, during the pandemic, we focused primarily on ensuring continuity of our production, tackling numerous challenges to make sure that the necessary medicines remain available…
We are even more proud of this award, as it was the employees of our industry themselves who indicated who the best employer is, in an anonymous and objective survey. This award proves that our joint contribution to the atmosphere and climate of our company is noticed and appreciated on…
Polpharma received this highest award for the eighth time. The Golden Leaf is awarded to companies for which sustainable development is a key element of strategic activities in business and in relations with stakeholders. The ratings were granted on the basis of a questionnaire completed by the companies, prepared in accordance…
EcoVadis is the world's largest independent rating agency verifying companies for sustainability. The EcoVadis Silver Medal places Polpharma among the top 25% of companies evaluated by EcoVadis, and there are more than 100,000 such organizations worldwide. In addition, we are among the top 12% of companies rated by EcoVadis in…
For the 12th time “Polityka” weekly, the advisory firm Deloitte and the Responsible Business Forum have honoured Polish leaders in sustainable development and ESG as part of the CSR Leaves Awards. The organisers analysed the approach of companies from the perspective of environmental, social and corporate governance aspects. The ratings…
Among the awarded projects by Polpharma are: Development and advancement of inhaled complex generic drugs for the treatment of respiratory diseases such as COPD and asthma – this project aims to create modern medications that will improve the quality of life for patients with respiratory diseases. Development and advancement of…
“The European Commission is implementing the STEP programme to support the development of breakthrough critical technologies that can strengthen the EU economy and reduce its dependence on third countries. Among the priority areas are biotechnologies, recognised as crucial for Europe’s future development and security,” explains Wojciech Wysocki, Deputy Head of…
The initial period of the COVID-19 pandemic demonstrated the importance of becoming independent from foreign supplies of medical resources to the Polish population. Thanks to the great mobilization of scientists, working hand in hand with businesses and benefitting from government assistance, the final version of the first Polish genetic test…
We are proud to have been a pillar of drug safety in Poland and a leader among pharmaceutical companies for years. Please visit our History site to discover more!
The weekly magazine "Polityka," in collaboration with Deloitte consulting firm and the Responsible Business Forum, has recognized Polish ESG leaders for the 13th time as part of the POLITYKA ESG Leaf ranking. The Silver ESG Leaf was awarded to companies that declare in their daily operational activities to take into…
The aim of the "Compliance Awards" competition is to increase market awareness and reward particular achievements in the area of compliance management, both for individuals and the achievements of the entire organization. The competition selects personalities and compliance projects of a unique nature. Applications are assessed by a jury composed…
Polpharma is the largest Polish manufacturer of active pharmaceutical ingredients (APIs), or active ingredients for the production of finished drug forms. They are available in more than 60 countries, including the largest markets: USA, TOP5EU, in Japan, Korea, Brazil, China and many others. In 2021, Polpharma launched a comprehensive investment…
Ecovisit is an educational and social campaign addressed to doctors and pharmacists. The idea is to educate our clients on new technologies and e-visits, as well as climate protection. For each online meeting of a Polpharma medical representative with a pharmacist or doctor, which lasts longer than 5 minutes, we…
The festive atmosphere will be evoked by the most popular Christmas carols and pastorals, which have been sung at the Christmas Eve table by generations of Polish families and represent the essence of Christmas magic. This year, new versions of the popular Christmas carols will be performed by: Katarzyna Cerekwicka,…
In practical terms, the implemented criteria and solutions include a number of useful amenities, such as ensuring appropriate widths of corridors and passageways, providing additional solutions in toilets, or adding new functionalities to the room booking system in order to make it easier to use for people with disabilities. In…
Warszawskie Zakłady Farmaceutyczne Polfa S.A. invites tenders for the purchase of used filling and packaging line for prefilled syringes. The line includes the following devices: Filling device Groninger FSE 3000 / MA 100, year: 1997, Labeller Groninger SMKE 3000, year: 2006, Blistering device CAM M92, year: 2006. Tenders containing: the…
In connection with the implementation of the project entitled "Development and introduction to the market of the first non-antibiotic product for the treatment of infectious eye diseases with an innovative ophthalmological composition in the form of eye drops, containing an active substance - povidone iodine" funded by the state budget…
In connection with the implementation of the project titled “Development and introduction to the medical market of the first non-antibiotic product in the treatment of infectious eye diseases – an innovative pharmaceutical form containing an antiseptic substance”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma…
In connection with the implementation of the project entitled. „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety” financed from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., ask for the submission of offers for the analysis of…
In connection with the implementation of the project entitled "Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety" financed from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A. asks for an offer for the provision of services in…
In connection with the implementation of the project titled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., you are kindly requested to submit a bid for the…
In connection with the implementation of the project titled “ Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for the purchase and supply of the raw…
In connection with the implementation of the project titled “ Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for the purchase and supply of the raw…
In connection with the implementation of the project titled “ Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for the purchase and delivery of RNA…
In connection with the implementation of the project titled “ Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for the purchase and delivery of RNA…
In connection with the implementation of the project titled “ Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for the purchase and delivery of RNA…
In connection with the implementation of the project titled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., you are kindly requested to submit a bid for the…
In connection with the implementation of the project titled “ Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for the purchase and delivery of RNA…
In connection with the implementation of the project titled “ Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zaklady Farmaceutyczne Polpharma S.A., requested to submit a bid for the purchase and delivery of specialty…
In connection with the implementation of the project titled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., you are kindly requested to submit a bid for the…
In connection with the implementation of the project titled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., you are kindly requested to submit a bid for the…
In connection with the implementation of the project titled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for purchase and delivery of raw materials for…
In connection with the implementation of the project titled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for purchase and delivery of raw materials for…
In connection with the implementation of the project titled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for purchase and delivery of raw materials for…
In connection with the implementation of the project titled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for purchase and delivery of an oligonucleotide analytical…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for the purchase and…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for the purchase and…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for the purchase and…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for the purchase and supply of…
In connection with the implementation of the project entitled "Development of a universal fastresponse platform, based on RNA technology, ensuring the national drug and epidemiological safety" funded by the state budget from the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., are requesting bids for the provision of services for conducting analytical…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for for the purchase and supply…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for the purchase and supply of…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for the purchase and supply of…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for the purchase and supply…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for the purchase and supply…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for for the purchase and supply…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for for the purchase and supply…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for the purchase and supply…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for the purchase and supply…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for for the purchase and supply…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for the purchase and supply…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for the purchase and supply…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for the purchase and supply…
In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids for the purchase and supply…
In connection with the implementation of the project titled “ Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for the purchase and supply of RNA oligonucleotide…
In connection with the implementation of the project titled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., you are kindly requested to submit a bid for the…
In connection with the implementation of the project titled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for the purchase and supply of the oligonucleotide analytical…
In connection with the implementation of the project titled “ Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for the purchase and supply of the oligonucleotide…
In connection with the implementation of the project titled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for purchase and delivery of raw materials for…
In connection with the implementation of the project titled „Design and development of an innovative solution - a complex, three-component medicinal product targeting the treatment of hypertension”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids concerning the purchase…
In connection with the implementation of the project titled “Development and development of an innovative solution – a complex, three-component medicinal product, aimed at the treatment of hypertension”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for purchase and delivery of active…
In connection with the implementation of the project titled “Development and development of an innovative solution – a complex, three-component medicinal product, aimed at the treatment of hypertension”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for purchase and delivery of active…
In connection with the implementation of the project titled „Design and development of an innovative solution - a complex, three-component medicinal product targeting the treatment of hypertension”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids concerning the purchase…
In connection with the implementation of the project titled „Design and development of an innovative solution - a complex, three-component medicinal product targeting the treatment of hypertension”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids concerning the purchase…
In connection with the implementation of the project titled „Design and development of an innovative solution - a complex, three-component medicinal product targeting the treatment of hypertension”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids concerning the purchase and supply…
In connection with the implementation of the project titled „Design and development of an innovative solution - a complex, three-component medicinal product targeting the treatment of hypertension”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests that you submit bids concerning the purchase and supply…
In connection with the implementation of the project titled „Design and development of an innovative solution - a complex, three-component medicinal product targeting the treatment of hypertension”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests for offers to conduct a pharmacokinetic study. Details of…
In connection with the implementation of the project titled „Design and development of an innovative solution - a complex, three-component medicinal product targeting the treatment of hypertension”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests for offers to conduct a phase IV study. …
In connection with the implementation of the project entitled "Design and development of an innovative solution - a complex, three-component medicinal product targeting the therapy of arterial hypertension", co-financed from the state budget under competitions held by the Medical Research Agency, Pharmaceutical Plant "Polpharma" S.A., is requesting bids for the purchase…
In connection with the implementation of the project titled „Design and development of an innovative solution - a complex, three-component medicinal product targeting the treatment of hypertension”, financed from the state budget funds from the Medical Research Agency, Zakłady Farmaceutyczne „Polpharma” S.A., requests for offers to conduct a clinical phase IV…
In connection with the implementation of the project entitled "Development of a universal fastresponse platform, based on RNA technology, ensuring the national drug and epidemiological safety" funded by the state budget from the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., are requesting bids for the provision of services for conducting…
In connection with the implementation of the project entitled "Development of a universal fastresponse platform, based on RNA technology, ensuring the national drug and epidemiological safety" funded by the state budget from the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., are requesting bids for the provision of services for conducting…
In connection with the implementation of the project entitled "Development of a universal fastresponse platform, based on RNA technology, ensuring the national drug and epidemiological safety" funded by the state budget from the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., are requesting bids for the provision of services for conducting…
In connection with the implementation of the project titled “Design and development of an innovative solution – a generic drug of the GLP-1 receptor agonist class for the treatment of type 2 diabetes”,” funded from the state budget by the Medical Research Agency, WZA Polfa Warszawa S.A., you are kindly requested to submit a bid…
In connection with the implementation of the project titled “Design and development of an innovative solution – a generic drug of the GLP-1 receptor agonist class for the treatment of type 2 diabetes”,” funded from the state budget by the Medical Research Agency, ZF Polpharma S.A., you are kindly requested…
In connection with the implementation of the project titled “Design and development of an innovative solution – a generic drug of the GLP-1 receptor agonist class for the treatment of type 2 diabetes”,” funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for…
In connection with the implementation of the project titled “Design and development of an innovative solution – a generic drug of the GLP-1 receptor agonist class for the treatment of type 2 diabetes”,” funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for…
In connection with the implementation of the project titled “Design and development of an innovative solution – a generic drug of the GLP-1 receptor agonist class for the treatment of type 2 diabetes”,” funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for…
In connection with the implementation of the project titled “Design and development of an innovative solution - a drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for…
In connection with the implementation of the project titled “Design and development of an innovative solution - a drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for…
In connection with the implementation of the project titled “Design and development of an innovative solution - a drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for…
In connection with the implementation of the project titled “Design and development of an innovative solution - a drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for…
In connection with the implementation of the project titled “Design and development of an innovative solution - a drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit…
In connection with the implementation of the project titled “Development and advancement of an innovative solution - a generic drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid…
In connection with the implementation of the project titled “Development and advancement of an innovative solution - a generic drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid…
In connection with the implementation of the project titled “Development and advancement of an innovative solution - a generic drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid…
In connection with the implementation of the project titled “Development and development of an innovative solution - a generic drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid…
In connection with the implementation of the project titled “Design and development of an innovative solution - a drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit…
In connection with the implementation of the project entitled "Development and development of an innovative solution - a generic drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes” financed from the state budget by the Medical Research Agency, Polpharma S.A. Pharmaceutical Works is asking…
The global healthcare ecosystem is undergoing a transformation by becoming more open to patients and incorporating new technologies. 90% of Europeans want to have access to their medical records through secure on-line tools, while 80% are ready to share their medical information as long as privacy is protected. Some of…
In connection with the implementation of the project entitled "Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety" funded by the state budget from the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., are requesting bids for the provision of services for a…
In connection with the implementation of the project entitled "Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety" funded by the state budget from the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., are requesting bids for the provision of services for a…
SIFI, Italian leader in the development and marketing of ophthalmic therapies, and Polpharma, the leader in the Polish pharmaceutical market, announce a commercial strategic partnership, mainly across Europe. The agreement will permit to enhance product portfolios andprovide a more comprehensive therapeutic range of ophthalmic therapies to the international market. Mutually identified areas of collaboration were established…
Polpharma has been included in the list of the most advanced companies in Poland in managing a culture of diversity and inclusion. Furthermore, the company has been recognized as an organization that has participated in the survey since its first edition and has made the most progress in building an…
In connection with the ongoing war on the territory of Ukraine, we would like to express our deepest compassion and solidarity with the suffering nation of this country. With great sadness and agitation we observe the worsening tragic situation for the Ukrainian civilians. We, together with our employees, are committed…
Polpharma was recognised in two categories: “Communications or PR Campaign of the Year - Reputation/Brand Management” (Stevie® Award) and “Re-Branding / Brand Renovation of the Year” (Bronze Stevie® Award). More than 3,900 projects from several dozen countries were entered in this year’s edition of the competition. Companies and agencies from…
Students chose Polpharma as an Ideal Employer in Natural Science category in the prestigious competition Universum Award 2018. Thanks to our activities in building the employer’s brand in the academic environment, we maintained the leading position in Natural Sciences category, where we overtook such players as Google, Microsoft, Nestle or…
Polpharma on the podium again! This year, we took second place in the “Most Attractive Employers Poland” ranking in the category of Exact Sciences. Students once again chose Polpharma as the Employer of Dreams, awarding us 2nd position in the Sciences category in the prestigious Universum Award 2022 survey. In…
Tenders containing: the completed tables “Szczegółowy wykaz wycofanego z użytkowania majątku – (Produkcja i Infrastruktura) 31.05.2023.xlsx” (Detailed List of Decommissioned Assets (Manufacturing and Infrastructure) 31/05/2023), indicating net unit prices, the following consent to personal data processing: “Having expressed my interest to submit a tender for the purchase of decommissioned assets…
Warszawskie Zakłady Farmaceutyczne POLFA Spółka Akcyjna with its registered office in Warsaw, at ul. Karolkowa 22/24 invites tenders for the purchase of decommissioned assets from technical Infrastcture area, including used: technical devices, installations and systems, measuring equipment, air compressors, chillers and laundry equipment as detailed in the attachment hereto (download…
The first stage of the "Medicines back to the Pharmacy" campaign aimed to educate and increase awareness in society of the importance of proper disposal of pharmaceuticals. In the second stage, we want to focus on activities in pharmacies, during which we will provide pharmacies and patients with educational tools…
At Polpharma, digitisation extends to the key areas: digital organisation, digital operations (production), digital product and digital market. Digital change affects every employee. There is one goal – to increase the company's business efficiency, and above all, to facilitate individual employees' daily tasks. "We prove that technology can effectively support…
The latest achievement by scientists from the PAS Institute of Bioorganic Chemistry and the Polish companies Polpharma, Medicofarma Future Synthesis and A&A Biotechnology, is a direct response to the needs of the public during the pandemic. The SARS-CoV-2 and influenza viruses cause two different diseases whose symptoms may be similar…
Jerzy Starak, together with the Polpharma Group – Poland’s largest drug manufacturer, which is owned by him – are providing systemic assistance to the Polish healthcare system. In order to effectively support the fight against the coronavirus, they have financed the purchase of a hundred ventilators for a total of…
The jurors appreciated the Leonardo program primarily for its creativity, ability to build commitment and innovative communication. The International Business Awards® is the world's largest awards program for business. This year, the competition received more than 3700 entries from 67 countries in dozens of categories, and the award was determined…
Simon Clark graduated from the Royal Agricultural College and obtained an HND (Higher National Diploma) in Agricultural Science and Economics. He is an accomplished commercial executive who has vast and long-term experience in FMCG, Consumer Healthcare (OTC) and Pharmaceuticals (both Rx and Gx) markets. He has over 20 years of…
The jury decided to grant our program with the highest awards in categories: Communications or PR Campaign of the Year - Issues Management Marketing Campaign of the Year - Brand Experience of the Year - Business-to-Business Marketing Campaign of the Year - Branded Utility of the Year in recognition of…
The Nicholas Hall CHC Marketing Awards 2023 recognizes the best marketing efforts and outstanding achievements in the pharmaceutical market. This is one of the most significant awards in the industry.
For 2023, Polpharma was honored with the title of Leader in Ethics. The Ethical Company competition has been the only one on the market for the past 10 years to recognize the best models of business conduct. Our way of doing business based on a foundation of the highest legal…
As the largest Polish pharmaceutical company, we want to help people live a healthy life in a healthy world, and care for the climate and the environment is an integral part of this mission. A key element of our energy transformation is to increase the share of renewable energy used…
In the report you will find, among other things: how we ensure drug safety for patients, what we do to develop our employees, how we care for the climate and the environment, review of our activities in the field of education and health prevention, our approach to innovation, and the…
X National Conference EPE - Interdisciplinary Faces of Contemporary Medicine in Theory and Practice for GPs and Family Medicine 2021 organized by Polpharma was noticed and awarded in the Events Reviews & 2022 Technology Forecast competition in two categories: 2021 The Best Event – CONFERENCE 2021 The Best Event –…
